Matinas BioPharma Holdings, Inc. (MTNB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Matinas BioPharma Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Matinas BioPharma Holdings, Inc. (MTNB) has returned -14.68% so far this year and -3.85% over the past 12 months. Over the last ten years, MTNB has returned -33.76% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Aug 18, 2014, MTNB's average daily return is +0.15%, while the average monthly return is +1.31%. At this rate, your investment would double in approximately 4.4 years.

Historically, 44% of months were positive and 56% were negative. The best month was Aug 2025 with a return of +106.8%, while the worst month was Oct 2024 at -82.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, MTNB closed higher 43% of trading days. The best single day was Oct 11, 2023 with a return of +313.6%, while the worst single day was Oct 31, 2024 at -67.9%.

Matinas BioPharma Holdings, Inc. has an annualized alpha of 31.94%, beta of 0.88, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 19, 2014.

• This stock participated in 217.06% of S&P 500 Index downside but only 49.46% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MTNB ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Matinas BioPharma Holdings, Inc. (MTNB) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Matinas BioPharma Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Matinas BioPharma Holdings, Inc. was 99.74%, occurring on Mar 31, 2026. The portfolio has not yet recovered.

The current Matinas BioPharma Holdings, Inc. drawdown is 99.74%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Matinas BioPharma Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Matinas BioPharma Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.